WAVE LIFE SCIENCES LTD (WVE)
SG9999014716 - Common Stock
WVE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of WVE is average, but there are quite some concerns on its profitability. WVE is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
WVE had negative earnings in the past year.
In the past year WVE has reported a negative cash flow from operations.
WVE had negative earnings in each of the past 5 years.
In the past 5 years WVE always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of WVE (-35.31%) is comparable to the rest of the industry.
WVE has a worse Return On Equity (-1676.98%) than 86.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.31% | ||
| ROE | -1676.98% | ||
| ROIC | N/A |
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for WVE has been increased compared to 1 year ago.
WVE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.19, we must say that WVE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.19, WVE perfoms like the industry average, outperforming 41.15% of the companies in the same industry.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.19 |
ROIC/WACCN/A
WACC9.04%
2.3 Liquidity
WVE has a Current Ratio of 0.99. This is a bad value and indicates that WVE is not financially healthy enough and could expect problems in meeting its short term obligations.
WVE has a worse Current ratio (0.99) than 85.94% of its industry peers.
A Quick Ratio of 0.99 indicates that WVE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.99, WVE is doing worse than 80.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.09% over the past year.
Looking at the last year, WVE shows a very strong growth in Revenue. The Revenue has grown by 202.15%.
The Revenue has been growing by 51.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)202.15%
Revenue growth 3Y78.03%
Revenue growth 5Y51.05%
Sales Q2Q%-10.92%
3.2 Future
The Earnings Per Share is expected to grow by 19.03% on average over the next years. This is quite good.
WVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.22% yearly.
EPS Next Y-86.08%
EPS Next 2Y-34.15%
EPS Next 3Y-20.5%
EPS Next 5Y19.03%
Revenue Next Year-32.87%
Revenue Next 2Y-20.34%
Revenue Next 3Y-2.49%
Revenue Next 5Y25.22%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
WVE's earnings are expected to decrease with -20.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.15%
EPS Next 3Y-20.5%
5. Dividend
5.1 Amount
No dividends for WVE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
WAVE LIFE SCIENCES LTD
NASDAQ:WVE (11/4/2024, 8:00:02 PM)
After market: 13.79 0 (0%)13.79
-0.04 (-0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.01B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.31% | ||
| ROE | -1676.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)58.09%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-86.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)202.15%
Revenue growth 3Y78.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y